DBV Technologies SA - American (DBVT) Q2 2024 Earnings Report

461 Followers

Previous Report: Q1 2024

Next Report: Q3 2024

DBVT Q2 2024 EPS Results

Actual EPS-$1.70

Consensus EPS-$2.23

Beat/MissBeat by +$0.53

One Year Ago EPS-$2.60

DBVT Q2 2024 Revenue Results

Actual Revenue$0.00

Expected Revenue$1.68M

Beat/MissMissed by -$1.68M

YoY Revenue Growth―

Earnings Announcement Details

QuarterQ2 2024

Date07/30/2024

TimeAfter Close

Conference CallTuesday, July 30, 2024

DBVT Upcoming Earnings

DBV Technologies SA - American's next earnings date is estimated for October 28, 2026, based on past reporting schedules.

Q2 2024 Earnings Call Audio

DBVT Q2 2024 Earnings Call

0:00 / 0:00

Q2 2024 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2024 Earnings Call Summary

Q2 2024

Earnings Call Date:Jul 30, 2024|

% Change Since:

Earnings Call Sentiment|Positive

The earnings call presents a positive outlook with significant progress in Viaskin Peanut development and financial management. However, regulatory challenges and increased operating expenses pose some concerns. The overall sentiment is cautiously optimistic with a positive tilt due to successful trial milestones and extended cash runway.

Company Guidance

During the DBV Technologies Q2 2024 earnings call, the company provided several key updates on its development programs and financial outlook. DBV is advancing its Viaskin Peanut candidate for treating peanut allergies in children aged 1 to 7. The VITESSE Phase III trial for children aged 4 to 7 is progressing well, with patient enrollment expected to complete by the end of Q3 2024. The company is also addressing the FDA's feedback on its COMFORT Toddlers supplemental safety study, which supports the Biologics License Application for the 1 to 3 age group. Additionally, DBV Technologies has extended its cash runway into Q1 2025 due to cost-saving measures, despite a net loss of $60.5 million in H1 2024. The company remains focused on achieving regulatory approval and advancing its clinical trials, with anticipated milestones set for the remainder of the year.

Viaskin Peanut Development Progress

Successful results from the Phase III efficacy study, EPITOPE, for toddlers aged 1 to 3 years met its primary endpoint. Enrollment for the VITESSE Phase III trial in children aged 4 to 7 years is expected to complete by the end of Q3 2024.

Cash Runway Extension

Due to cost-saving measures, DBV Technologies has extended its cash runway into Q1 of 2025, an extension from the previous estimate of year-end 2024.

Financial Efficiency

Operating income for the first semester of 2024 reached $2.6 million, with efforts to maximize efficiency and maintain disciplined cash management.

DBVT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Oct 28, 2026	2026 (Q3)	-0.14 / -	-0.24	―
Jul 16, 2026	2026 (Q2)	-0.11 / -0.12	-0.31	61.29% (+0.19)
Apr 30, 2026	2026 (Q1)	-0.13 / -0.11	-0.26	57.69% (+0.15)
Mar 26, 2026	2025 (Q4)	-0.18 / -0.24	-0.24	0.00% (0.00)
Oct 28, 2025	2025 (Q3)	-0.32 / -0.24	-1.6	85.00% (+1.36)
Jul 29, 2025	2025 (Q2)	-0.18 / -0.31	-1.7	81.76% (+1.39)
Apr 30, 2025	2025 (Q1)	-0.24 / -0.26	-2.8	90.71% (+2.54)
Mar 24, 2025	2024 (Q4)	-0.22 / -0.24	-1.2	80.00% (+0.96)
Nov 06, 2024	2024 (Q3)	-1.80 / -1.60	-1.7	5.88% (+0.10)
Jul 30, 2024	2024 (Q2)	-2.23 / -1.70	-2.6	34.62% (+0.90)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed